Apatinib, as a specifically targeting VEGFR‐2 and oral receptor tyrosine kinase inhibitor, has been shown that it could inhibit the angiogenesis of tumor through prohibiting VEGF‐promoted tumor development. This evidence concerns the gene KDR and neoplasm.